# Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

> **NCT01542060** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 298 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart 30

## Key facts

- **NCT ID:** NCT01542060
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 298 (ACTUAL)
- **Last updated:** 2012-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542060, "Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01542060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*